Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Germline predisposition to AML

Lucy Godley • 1 Jul 2020
ESH AL 2020
Acute Myeloid Leukemia Leukemia

Lucy Godley, MD, PhD, University of Chicago, Chicago, IL, highlights the importance of identifying germline predisposition to hematopoietic malignancies and outlines how to recognize and manage these cases. Additionally, Dr Godley discusses how to differentiate between germline and somatic mutations. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Lucy Godley

2:27
Germline predisposition to myeloid malignancies: emerging research
Lucy Godley • 1 Jul 2020
1:41
The impact of germline mutations on AML managment
Lucy Godley • 1 Jul 2020

Related Videos

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals